Kimball Electronics, Inc. (NASDAQ: KE) – Q2 2026 Earnings
Kimball Electronics, Inc. (NASDAQ: KE) – Q2 2026 Earnings
Press release and earnings call link
Earnings Release Date: Feb. 4, 2026
Stock Price: $31.06
Market Cap: $764.2 million
Q2 2026 sales of $341.3 million vs $357.4 million in the prior year
Q2 2026 GAAP diluted EPS of $0.15 vs $0.14 in the prior year
Q2 2026 GAAP basic EPS of $0.15 vs $0.14 in the prior year
Q2 2026 Non-GAAP diluted EPS of $0.28 vs $0.29 in the prior year
Q2 2026 Non-GAAP basic EPS of $0.28 vs $0.29 in the prior year
Overview: Kimball is a global contract manufacturer that builds electronics and higher-level assemblies for customers across Automotive, Medical, and Industrial end markets.
Revenue drivers (what it does): Primarily EMS (Electronics Manufacturing Services) plus expanding CMO (Contract Manufacturing Organization) work in medical (manufacturing in regulated medical-device categories, often with more process rigor and longer product life cycles).
Customer/end markets: Largest exposure remains Automotive (48% of Q2 sales), with Medical growing and now 28% of sales; Industrial is 24%.
Positioning / niche: Management is explicitly repositioning toward being a medical-focused CMO / “solutions” partner (design/engineering, supply chain, precision plastics, higher-level assemblies), not “just” a traditional EMS provider.
Recent trajectory: Q2 revenue declined 5% YoY, but profitability improved (adjusted operating margin 4.5%, +80 bps). The “story” is mix-shift: Medical +15% offsetting Automotive -13% and Industrial -5%.
Near-term themes: Raised FY26 guidance on stronger Medical + European automotive ramps, while absorbing near-term margin drag from the new Indianapolis medical facility and ongoing restructuring.
Competitive Advantage Insights
Press Release vs Call Transcript Comparison
Press release is “results + metrics”; call is “bridge to forward earnings power.” The PR gives clean KPI disclosure (vertical revenue, margins, CCD, open orders). The call explains what changes next (EB100 anniversary, Indy drag duration, Q3 comp quirks, where program wins could land).
The call subtly argues Kimball deserves a different framework: less “auto volume cycle,” more “medical capacity partner with regulated manufacturing + higher-level assembly.” That’s an attempt to shift the debate from near-term revenue softness to medium-term mix and margin quality.
Positive Insights
Negative Insights
Investor Underappreciation Signals
✅Indy drag vs. payoff gap — Near-term margin pressure from running two facilities and higher depreciation may mask improving underlying profitability; the perception can flip as the Indy CMO pipeline converts into revenue and the legacy site is closed.
✅Medical growth breadth — Medical growth was not driven by one legacy sub-category and was split across regions and sub-verticals; investors may overlook this because the headline is “company sales down,” but diversified medical traction can change the durability narrative.
✅Q3 comp trap — The prior-year $24M consigned inventory sale can distort reported medical growth next quarter; investors might misread a “slow” growth print that is mostly optics, and management’s planned disclosure can correct that.
✅Automotive inflection timing — Automotive headwinds from the EB100 program anniversary are expected to clear in Q3 while European ramps build; investors may still anchor to the -13% Q2 decline until prints show the inflection.
✅Lift-and-shift upside — Increased “lift-and-shift” discussions can create step-function wins (customers exiting in-house manufacturing); investors may overlook it because it’s not quantified in the PR, but conversions can quickly change the revenue slope.
Tariff Risk
What they said: Management explicitly linked tariffs to pressure in U.S. automotive and said they’re monitoring FY27 outlook as consumers respond to tariff impacts, subsidy changes, and broader economic concerns.
Where it hits: The discussion frames tariffs primarily as a demand-side headwind (volumes in North America automotive), rather than a direct cost/supply-chain disruption item in this transcript.
Mitigation actions mentioned: No concrete mitigation actions (price pass-through, supply-chain shifts, renegotiations) were detailed on the call; instead, the mitigation implied is portfolio balance (medical growth outpacing) and restructuring/cost alignment to end-market demand.
Competitive/innovation effects: They did not claim tariffs improve their competitive position; the tone suggests tariffs add uncertainty and could weigh on North America auto volumes.
Forward-looking framing: Tariffs are explicitly a key variable for FY27 visibility, which is an investor risk because it can keep forward multiples constrained even after a near-term guidance raise.
Hot Stock Trends Analysis
Previous Earnings Call
Quarter-over-quarter comparison (Previous Analysis)
In Q1, Kimball’s story was “we’ve stabilized”: sales slightly down but medical is growing double digits, margins are improving from restructuring/Tampa closure, the balance sheet is cleaner, and management is building a medical CMO platform (including the Indianapolis facility) to drive a return to profitable growth in FY27.By Q2, the story becomes “the transition is starting to show up in guidance”: medical growth remains strong, European automotive ramps are helping offset North America weakness, and management is confident enough to raise FY26 guidance while simultaneously launching major strategic signals (Indy grand opening + rebrand to Kimball Solutions). The market-facing message shifts from “we’re getting ready for the future” to “we’re actively reshaping the company and it’s beginning to change the earnings trajectory,” even as near-term margin and cash-cycle noise rises due to Indy ramp and macro uncertainty.
Year-over-year comparison (Previous Analysis)
In Q2 FY2025, Kimball’s narrative was about stabilization and survival. Management acknowledged a prolonged downturn, cut guidance, focused on balance-sheet repair, and asked investors for patience while restructuring the business and laying the groundwork for a medical-focused future.
By Q2 FY2026, the story had shifted to execution and emergence. Medical growth is consistently double-digit, margins are improving, guidance is raised, and the Indianapolis facility and rebrand serve as tangible proof points that the transformation is no longer theoretical. While macro risks and near-term margin drag remain, the company’s messaging has moved from “preparing for a turnaround” to “actively reshaping the earnings profile,” marking a clear inflection in confidence and strategic posture.
Final Takeaway
Kimball Electronics is in a mix-shift and capability-expansion phase, focusing on scaling its medical CMO strategy while stabilizing automotive and managing industrial softness. While the raised guidance and sustained medical growth are meaningful positives, near-term results face headwinds from tariff-related auto demand pressure and a temporary margin drag from the Indianapolis facility ramp. Execution on medical program conversion, automotive stabilization in Q3/Q4, and working-capital normalization will drive the next leg of performance. Verdict: Hold, with upside if Indy ramps into margin-accretive revenue and auto stabilizes as guided, and downside if tariffs/soft demand overwhelm the cost offsets.